Table 4 Top canonical pathways modulated by L-OHP in HT-29R

Interferon signaling

2,51E-05

1.94E-01

IFIT3, IFIT1, IFITM1, MX1, IRF9, PSMB8, STAT1

Methylglyoxal degradation III

2,04E-04

1.74E-01

AKR7A3, AKR1C1/AKR1C2, AKR1B10, AKR1B1

Cholesterol biosynthesis I

4,17E-04

1E-01

SQLE, DHCR7, MSMO1, CYP51A1

Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)

4,17E-04

1E-01

SQLE, DHCR7, MSMO1, CYP51A1

Cholesterol biosynthesis III (via Desmosterol)

4,17E-04

1E-01

SQLE, DHCR7, MSMO1, CYP51A1

LXR/RXR activation

7,76E-04

8.09E-02

SCD, TTR, LDLR, SREBF1, AMBP, SERPINA1, PTGS2, TLR3, IL1RAP, CYP51A1, AGT

Mevalonate pathway I

4,47E-03

1.07E-01

IDI1, HMGCS2, HMGCS1

Creatine-phosphate biosynthesis

4,90E-03

3.33E-01

CKB, CKMT1A/CKMT1B, LCMT2

Activation of IRF by Cytosolic pattern recognition receptors

5,75E-03

8.33E-02

DHX58, IFIH1, IRF9, STAT1, IFIT2, ISG15

Tryptophan degradation X (Mammalian, via Tryptamine)

1,05E-02

1.03E-01

ALDH1A3, DDC, MAOA

Zymosterol biosynthesis

1,17E-02

9.09E-02

MSMO1, CYP51A1

Maturity onset diabetes of young (MODY) signaling

1,95E-02

9.68E-02

FOXA2, FABP1, HNF4A

Eicosanoid signaling

2,19E-02

6.25E-02

DPEP1, PNPLA3, RARRES3, PTGS2, ALOX5

Ketogenesis

2,69E-02

9.52E-02

HMGCS2, HMGCS1

Acyl-CoA hydrolysis

3,31E-02

1.25E-01

ACOT4, HNF4A

PXR/RXR activation

3,47E-02

5.75E-02

SCD, NR0B2, CYP2B6, HMGCS2, HNF4A

Colorectal cancer metastasis signaling

3,89E-02

4.67E-02

VEGFA, MMP7, RND3, TGFB1, FZD3, GNB5, TGFB2, PTGS2, TLR3, STAT1, FNBP1, WNT5A

Aryl hydrocarbon receptor signaling

4,17E-02

4.97E-02

TGM2, TFF1, NR0B2, ALDH1A3, TGFB1, TGFB2, ALDH18A1,NRIP1

p38 MAPK signaling

4,27E-02

5.98E-02

DDIT3, TGFB1, TGFB2, MKNK2, RPS6KA2, STAT1, IL1RAP

Choline biosynthesis III

4.64E-02

9.09E-02

CHPT1,PLD1

Histamine degradation

4.64E-02

6.9E-02

ALDH1A3,ABP1

Adenosine nucleotides degradation II

4.64E-02

8E-02

NT5E, ADA

Wnt/β-catenin signaling

5E-02

5.2E-02

MMP7, CDH3, TGFB1, PPP2R3A, TGFBR3, FZD3, CD44, TGFB2, WNT5A